Shots:
- Ultragenyx has entered into a definitive agreement to sell a Rare Pediatric Disease PRV for $210M, provide Ultragenyx with significant non-dilutive capital to advance therapies for rare & ultra-rare diseases
- Rare Pediatric Disease PRV was received following FDA approval of Genglycos (pariglasgene brecaparvovec-opnr), the first treatment targeting the underlying cause of glycogen storage disease type Ia
- The PRV transaction remains subject to customary closing conditions, including the expiration of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act
Ref: Globenewswire | Image: Ultragenyx | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
